IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y - Zacks Investment Research
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y - Zacks Investment Research（摘要待生成）
IQVIA Hldgs Q3 2026 Earnings Call Transcript - Benzinga
IQVIA Hldgs Q3 2026 Earnings Call Transcript - Benzinga（摘要待生成）
Global Drug Development Services Market Report 2026 | Capitalize on AI and Precision Medicine as IQVIA, Labcorp, Lonza, ICON, and WuXi AppTec Compete for a $50.26B Market by 2030 - Yahoo Finance
Global Drug Development Services Market Report 2026 | Capitalize on AI and Precision Medicine as IQVIA, Labcorp, Lonza, ICON, and WuXi AppTec Compete for a $50.26B Market by 2030 - Yahoo Finance（摘要待生成）
JPMorgan raises IQVIA price target to $295 from $285
On Oct. 14, JPMorgan raised its IQVIA target to $295 from $285 and maintained its rating. FactSet-polled analysts’ average rating was Buy and mean target $298.06. The report gave no share-price or peer reaction.
IQVIA selects Veeva clinical operations applications
On Oct. 13, IQVIA announced it selected Veeva Clinical Operations applications for clinical development studies. Veeva’s shares rose 2.8% that afternoon, according to StockStory; the available report did not give IQVIA’s or CRO peers’ reaction.
Deutsche Bank cuts IQVIA price target to $179 from $191
On Oct. 15, Deutsche Bank lowered its IQVIA price target to $179 from $191. MarketScreener listed IQV at $265.88 at the Oct. 19 close; the report did not state a stock-market reaction or rationale.
Stifel raises IQVIA stock price target on improving market backdrop
Stifel raises IQVIA stock price target on improving market backdrop（摘要待生成）
Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303
Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303（摘要待生成）
Stifel raises IQVIA price target to $303
On October 14, Stifel analyst Shlomo Rosenbaum maintained Buy and raised the IQVIA price target from $276 to $303.